Articles dans des revues avec comité de lecture (48)
  1. 36. Langer, I., Vertongen, P., Perret, J., Cnudde, J., Grégoire, F., De Neef, P., Robberecht, P., & Waelbroeck, M. (2002). VPAC(1) receptors have different agonist efficacy profiles on membrane and intact cells. Cellular signalling, 14(8), 689-694.
  2. 37. Perret, J., Vertongen, P., Solano Haro, R., Langer, I., Cnudde, J. G., Robberecht, P., & Waelbroeck, M. (2002). Two tyrosine residues in the first transmembrane helix of the human vasoactive intestinal peptide receptors play a role in supporting the active conformation. British Journal of Pharmacology, 136(7), 1042-1048. doi:10.1038/sj.bjp.0704802
  3. 38. Langer, I., Vertongen, P., Perret, J., Waelbroeck, M., & Robberecht, P. (2002). A small sequence in the third intracellular loop of the VPAC(1) receptor is responsible for its efficient coupling to the calcium effector. Biochemical Society transactions, 30(4), 447-450. doi:10.1042/
  4. 39. Langer, I., Vertongen, P., Perret, J., Waelbroeck, M., & Robberecht, P. (2002). A small sequence in the third intracellular loop of the VPAC(1) receptor is responsible for its efficient coupling to the calcium effector. Molecular endocrinology, 16(5), 1089-1096.
  5. 40. Perret, J., Van Craenenbroeck, M., Langer, I., Vertongen, P., Grégoire, F., Robberecht, P., & Waelbroeck, M. (2002). Mutational analysis of the glucagon receptor: similarities with the vasoactive intestinal peptide (VIP)/pituitary adenylate cyclase-activating peptide (PACAP)/secretin receptors for recognition of the ligand's third residue. Biochemical journal, 362(Pt 2), 389-394.
  6. 41. Lema Kisoka, R., Hayez, N., Langer, I., Robberecht, P., Sariban, E., & Delporte, C. (2001). Characterization of functional VIP/PACAP receptors in the human erythroleukemic HEL cell line. Peptides, 22(12), 2155-2162.
  7. 42. Langer, I., Perret, J., Vertongen, P., Waelbroeck, M., & Robberecht, P. (2001). Vasoactive intestinal peptide (VIP) stimulates [Ca2+]i and cyclic AMPin CHO cells expressing Galpha16. Cell calcium, 30(4), 229-234. doi:10.1054/ceca.2001.0230
  8. 43. Vertongen, P., Solano Haro, R., Perret, J., Langer, I., Robberecht, P., & Waelbroeck, M. (2001). Mutational analysis of the human vasoactive intestinal peptide receptor subtype VPAC(2): role of basic residues in the second transmembrane helix. British Journal of Pharmacology, 133(8), 1249-1254. doi:10.1038/sj.bjp.0704195
  9. 44. Solano Haro, R., Langer, I., Perret, J., Vertongen, P., Juarranz Moratilla, M. G., Robberecht, P., & Waelbroeck, M. (2001). Two basic residues of the h-VPAC1 receptor second transmembrane helix are essential for ligand binding and signal transduction. The Journal of biological chemistry, 276(2), 1084-1088. doi:10.1074/jbc.M007696200
  10. 45. Langer, I., Atassi, G., Robberecht, P., & Grégoire, A. (2000). Eriochrome Black T inhibits endothelial cell growth through S-phase blockade. European journal of pharmacology, 399(2-3), 85-90.
  11. 46. Langer, I., Vertongen, P., Perret, J., Fontaine, J., Atassi, G., & Robberecht, P. (2000). Expression of vascular endothelial growth factor (VEGF) and VEGF receptors in human neuroblastomas. Medical and pediatric oncology, 34(6), 386-393.
  12. 47. Malonne, H., Langer, I., Kiss, R., & Atassi, G. (1999). Mechanisms of tumor angiogenesis and therapeutic implications: angiogenesis inhibitors. Clinical & experimental metastasis, 17(1), 1-14.
    13. << Précédent 1 2 3 4 5 6 7 8 Suivant >>